Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Biogen

Biogen
1978 FOUNDED
PUBLIC STATUS
5K-10K EMPLOYEES
BIIB STOCK SYMBOL
56 INVESTMENTS
$229.11 SHARE PRICE (As of Thursday Closing)
Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Website
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Biogen’s full profile, request a free trial.

Biogen Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$216.12 - $388.67 $44.4B $235.04 $23.29 2.5M 194M

Biogen Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 48,888,522 62,864,642 68,981,008 64,799,671
Revenue 13,811,600 13,452,900 12,273,900 11,448,800
EBITDA 7,315,700 7,004,300 6,382,100 5,812,300
Net Income 4,666,600 4,430,700 2,539,100 3,702,800
Total Assets 26,445,500 25,288,900 23,652,600 22,876,800
Total Debt 5,943,200 5,936,500 5,938,200 6,517,400
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Biogen‘s full profile, request access.

Request full access to PitchBook

Biogen Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Celgene Pending Transaction (M&A) Summit, NJ 0000 000.00 000000&0 000.00
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 0000 00.000
0000000 Formerly VC-backed Boston, MA 0000 000000000
0000000-00000 0000 Corporation New York, NY 00000 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
To view this company’s complete list of competitors, request access »

Biogen Investments & Acquisitions (56)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 04-Mar-2019 000000000000000000 00000 Biotechnology 000000 000000000
0000000 0000000 31-Dec-2018 000000000 00000000 00000 Biotechnology 0000000 0000000
00000000 000 24-Jul-2018 000000000000000000 00000 Biotechnology
00000 000000000000 11-Jun-2018 000000000 00000000 000 Drug Discovery 000000 000000000
TMS (TMS-007 and Backup Compounds) 08-Jun-2018 Corporate Asset Purchase 0000 Buildings and Property 0000000 00000000
To view this company’s complete investment and acquisition history, request access »

Biogen Exits (22)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 00000000000 30-Mar-2017 00000 00000 00 0000 Completed
  • 8 buyers
00000 00 03-Nov-2015 00000 00000 00 000.00 Completed
  • 6 buyers
0000 00000 0000000 17-Jun-2014 00000 00000 00 0000 Completed
  • 8 buyers
0000000 17-Mar-2014 00000 00000 00 0000 Completed
  • 2 buyers
Probiodrug 04-Jan-2012 Later Stage VC 000.00 Completed
  • 9 buyers
To view this company’s complete exits history, request access »

Biogen Subsidiaries (4)

Company Name Industry Location Founded
AliveGen USA Biotechnology Thousand Oaks, CA 2014
00000000000 000000 Biotechnology Cambridge, United Kingdom 0000
0000000 Biotechnology NC 0000
0000000 Biotechnology South San Francisco, CA 0000
To view this company’s complete subsidiary history, request access »

Biogen Executive Team (68)

Name Title Board
Seat
Contact
Info
Michel Vounatsos Chief Executive Officer and Director
Jeffrey Capello Executive Vice President & Chief Financial Officer
Martin Dubuc Managing Director
Ginger Gregory Ph.D Executive Vice President and Chief Human Resources Officer
Christian Schubert Ph.D Director, Business Development & External Innovation

38 Former Executives

You’re viewing 5 of 68 executives. Get the full list »

Biogen Board Members (13)

Name Representing Role Since Contact
Info
000000000 000000 00.0 Self Director and Chairman, Corporate Governance Committee 000 0000
00000 000000 Self Director & Chairman, Finance Committee 000 0000
00000000 00000 Biogen Board Member & Chairman, Audit Committee 000 0000
0000 00000000 00 Self Board Member 000 0000
0000 000000 Biogen Board Member and Chairman, Risk Committee 000 0000

1 Former Board Member

You’re viewing 5 of 13 board members. Get the full list »